Entry Name Amplified FGFR to PI3K signaling pathway
Definition FGFR* -> PI3K -> PIP3 -> AKT -> MTOR
Expanded (2260v1,2263v1) -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475
Class Type Variant
Pathway Disease Gene 2260 FGFR1; fibroblast growth factor receptor 1
2263 FGFR2; fibroblast growth factor receptor 2
5290 PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
5291 PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
5293 PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
207 AKT1; AKT serine/threonine kinase 1
208 AKT2; AKT serine/threonine kinase 2
10000 AKT3; AKT serine/threonine kinase 3
2475 MTOR; mechanistic target of rapamycin
Variant 2260v1 (FGFR*) FGFR1 amplification
2263v1 (FGFR*) FGFR2 amplification
Metabolite C05981 Phosphatidylinositol-3,4,5-trisphosphate
Reference Authors Zhang MH, Man HT, Zhao XD, Dong N, Ma SL
Title Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).
Journal Reference Authors Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A
Title FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Journal Reference Authors Katoh M, Nakagama H
Title FGF receptors: cancer biology and therapeutics.
Journal Reference Authors Katoh M
Title FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies.
Journal Reference Authors Katoh M
Title Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics.
Journal LinkDB All DBs
